Ladies and gentlemen, welcome to the Sonova Holding AG half-year results 2021/2022 conference call and live webcast. I am Sandra, the Chorus Call operator. I would like to remind you that all participants will be in listen-only mode and the conference is being recorded. The presentation will be followed by a Q&A session. You can register for questions at any time by pressing star and one on your telephone. For operator assistance, please press star and zero. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Arnd Kaldowski, CEO. Please go ahead, sir. Sandra, thanks for the introduction. Good afternoon to everyone on the call. Thanks for making the time on the Monday here. Obviously, we come together to comment and then open up for questions with regard to our results scorecard of the first half year, 2021/2022. Let me quickly share who is in the room with me. I have the pleasure to have Birgit Conix with me, our CFO, and then Thomas Bernhardsgrütter from our Investor Relations team. Jumping to page 2, the standard disclaimer with regard to forward-looking statements. Everybody is well aware, and it is published. With that, I would like to jump to page 3 here. If you look at the highlights of the first half year, from our point of view, we're seeing a sustained positive momentum for Sonova on the growth above market, as well as continued good progress on the profitability of the business. That's supported by a market recovery, which I think is pretty good with regard to the situation we have in the environment. Looking at the market recovery, which has continued in the first half year, I think it's fair to say that there are some residual COVID-19 challenges remaining, very much different by geography. Some markets are a little higher than the normal two-year CAGR, other ones are lower. I will comment on the profile we're seeing by geography. Good sales momentum on our side, being here at the later part of the COVID-19 challenge, and from our point of view, carried by the latest product innovations, the Paradise last year, then the Naída CI Marvel processors, and then advancements to the Paradise this year in August. Also continued strong commercial execution and investment into our sales and marketing infrastructure in the various businesses. Positive sales momentum in HI, particularly driven by the Phonak Paradise. I'm sure you noted when you did the pre-read, good performance on the growth side in cochlear implants, clearly being now, since the launch of the new processors in a mode of recapturing market share. made further progress on the profitability, as one can see from the year-over-year, but also two-year CAGRs on the profit growth, and that despite our continued step-up in growth investments, which we'll share a little bit more in detail. Also since August, so for this period, August and September, quite some headwinds on the supply chain side, which I will highlight a little bit more about. From an outlook perspective for the full year, maintaining our guidance we gave for the full year on top and bottom line, despite the remaining COVID-19 headwinds, which may be a little bit more than we thought for the second half when we came into the year. Keep in mind, it's not so easy to make a call in April on where you wanna put the guidance, especially with the still, let's say, evolving COVID-19 environment plus the supply chain. I think the good progress we are making, the good momentum we have allow us to stay in the guidance range here. Going to page 5, the highlight numbers. Sales close to 50% in local currency year-over-year. Obviously, that was the low point of the COVID-19 pandemic. If you look at the 2-year CAGR, which we think is the fairest judgment on how we're doing as a market, but then also we as Sonova compared to others at 8.5% in LC, clearly setting us ahead of the normal market growth rates. Then on the EBITDA, 130% expansion versus prior year. More relevant to look at the two-year CAGR at 26.3%, showing that we have created significant leverage from a continuous improvement, but also structural improvement. You may remember the changes we made last year to the footprint, allowing us to strongly invest, but at the same time produce more profit. Nice development on the EPS side, obviously following the EBITDA side here. Then on the innovation side, continue to invest. That's in the P&L from a cost perspective, but also reaping the benefits on the products we launched recently. You see the reiteration of the guidance which we put out in May. Very quick note on page six, just to make sure I said it, there's no change to our big picture strategy. I think all of the ones at play, I could go in any of the six and explain what are the initiatives and what are we doing now, how are we doubling down on things? Clearly further progress as we progress ourselves here through the year. Page seven, a quick reminder on the most relevant innovation steps forward. On the Paradise side, just wanna remind two significant, let's say feature additions to Paradise in August. You can see we continue to do new platform every two years, but then significant advancements of the platform in the in-between year. We launched the ActiveVent, which is very relevant with regard to people with a severe to profound hearing loss, and has good reception in the market from its performance improvement. With the Audéo Life, the waterproofing on the hearing aids in all transparency, currently only available in some markets and at the higher end because that's one of the areas where we struggle with chip availability. It is in the market and finds positive reception, but it's not yet broad-based on the revenue side until we have worked through some chip supply issues there. On the Naída CI processor, we've brought over and launched this in the December, January timeframe, the Phonak Marvel technology to the Naída processors, and with it came the Sonova Made For All phone, making it very strong value proposition, not just for new people who are looking for an implant, but also as an upgrade to the existing installed base of electrodes. Moving on to page eight, and I'm reusing the slides we shared at the capital market just to remind and make some comments on progress. You may remember we said we wanna step up the bolt-on acquisition side for audiological care. We highlighted 70-100 million to be a good midterm target of capital deployment a year. We were in the good position to do some of those, end of last year, beginning of this year, and so that contributed some 5.2% on the audiological care growth rate in the first half year. We will continue on that journey, but clearly a good start to that elevated M&A bolt-on side. On page nine, I don't wanna repeat the numbers I already said, so I'm going to go a little bit selective here. If you look at the EBITDA side, I was still at the 130 percentage points in LC, clearly benefiting from higher sales, but also the structural optimization from last year, and I would say tight cost management where we didn't invest into incremental people for growth. On the growth side, we're leaning forward. Most relevant, the EBITDA margin side at 25.3%. That's up almost 900 basis points versus prior year, but almost 700 basis points to two years ago. Clearly the step-up is sustained. I think on the hearing instrument side, getting back to the discussion at the beginning of the year, we have been able to hold on to our leading position with the VA pretty much around the same number, which I would interpret as a good sign for the performance of our product relative to competition. On the audiological care side, I was talking about geographies which are struggling more versus less. I think audiological care with a good performance when we compare side by side to markets in the markets, but in the global rollout, roll-up somewhat less strongly growing than the wholesale business. This is pretty much coming from a footprint discussion. Our strongest countries are Germany, Belgium, Netherlands is pretty large. U.K. is one of the strongest, and these were the ones who in the first quarter, and then the three named here in the second quarter, were the slowest markets we've seen on the recovery. Clearly for that 40% of our book of business in AC, more of a headwind situation, which we think will level out over the period it takes until we're fully out of COVID in those markets. Then on the cochlear implant side, I will comment later in more detail, but I wanna give the highlight number here. If you look at the EBITDA margin, I think with some of you, we for many years now had the discussion, can this business get to double digit in the EBITDA? I think this half year shows it. We can. We've been at 13%, and that's the highest the segment ever had. This is based on good work with regard to obviously top line out of the Marvel processors, but at the same time, the work we've done over the years on the cost structure from a continuous improvement but also structural improvement perspective. It's fairly earned. We go to page 10. Don't wanna go too deep. Birgit will guide us more through the numbers. Just wanna highlight some of the bigger picture here on the two-year CAGR. You can see on the schedule we're providing you with the comparison versus prior year, comparison versus two years ago, and then the two-year CAGR. We do the two years ago because others have commented in that way, so it's easier for you to compare the numbers. We think the best way to look at it is the two-year CAGR. You can see the HI business is leading the three businesses with 10.5%. AC with the geo headwinds from a mix perspective at 6.3% in sales. In CI, 5.3%, I think the market is somewhat slower in the recovery. There are still hospitals who do not do elective surgeries. At the same time, the Field Corrective Action is in the middle of that two-year period. We lost market share. We said that last year after the Field Corrective Action, but since 9 months, we're now recovering some of that. Gross profit nicely above the sales growth, showing the fall through as well as the continuous improvement. Despite the growth investments, you can see that we're reasonably tight in the sum of all OpEx and how we grow the OpEx space. In our eyes, sustained HI market share gains and the best-in-class profitability. The next page is more to your benefit here to see the breakdown in the different components of growth. If you look at the organic, very strong organic growth in this year, you look at the two-year CAGR also with a 7.6%, a strong number. The M&A is a small proportion to all of that right now, although we'd like to do more from a bolt-on perspective. As you can see the negative FX effect here over a two-year period, while currently we're slightly positive. If we go to geographies on page 12 and focus on the two-year CAGR in the middle, you can see that while all of the geographies have a mid-single-digit to a high-single-digit growth rate in two-year CAGR, U.S. stands out with a 12.2%. That is the good work on the wholesale side because that's predominantly a wholesale market for us. We only have a small footprint from a retail. It is also that the market is recovering currently faster than the others. There are quite some pent-up demand on the way, but the 12.2% is not just pent-up demand, but it's also market share gain over the last 2 years in the U.S. I commented in EMEA on the AC slower markets. I think in the U.S., clearly there's market share gain on the independents, but also the private label contract as well as the sustained VA position are helpful here. If you look at the others in our world, that's Asia a little weaker, particularly because Japan, Australia, New Zealand had elements of lockdown in the first half year. In Canada, we also see a slower recovery because of the more careful opening scenarios of the government. Want to go a little bit more into detail on the hearing instrument segment. On page 14, want to cover on the blue boxes, which is the segment numbers. You see in the segment 8.8% two-year CAGR. You see the profitability at the 25.6, and us getting in the overall segment to a 26.5% margin level. I think I commented on the sales side, pretty much all of the elements. I'll get to the individual businesses in a second, but clearly strong performance on how we manage the cost structure. At the same time, as I said earlier, at least for two months in the half year period, more costs on the supply chain or the way you have to think about it. I think the freight was already elevated over the whole period. But since August, we do have certain chipsets more on the standard chips. Some other things we may integrate in accessories on a product like the Roger, where we may be short, and at the same time we're trying to buy on the broker level, which is more costly, sometimes far more costly than what you can get directly from the manufacturer. We integrate this as to some degree, more demand, but on the other hand, also people having bought a lot for their safety stocks. At this point of time, we do pay a significantly higher amount for those kind of chips than we normally would do. We expect this to continue for at least the next 6 months or for the second half of the year. It's hard to predict how long this will last. You hear many different, let's say, directions. We're thinking more on the 12 months, but clearly for the next 6 months, we have factored this into our guidance here. Just a couple of more comments on the hearing instrument segment. Our wholesale business, you can see the numbers on the top. We continue to invest strongly into R&D and in customer-facing resources in the markets because we think there's more market share to be gained over time, and we think that innovation continues to be an important driver of our ability to sell more. Talked about the ActiveVent in the Audéo Life. Important to note that the Unitron product also has migrated to the Paradise technology in the March, April timeframe, and we do see a very good growth there on the basis of the Paradise technology. On the lower bullet points, no major change, but continued work on sales funnel management in the different regions and also supporting our independents increasingly on the journey to find more leads. If we go to page 16, the audiological care business. Similar to the wholesale business, we continue to significantly invest into the business on the one end on the lead generation side, and on the other hand, on the World of Hearing concept and the greenfield openings. On the lead generation side, two elements as we discussed at the Capital Markets Day. We do build more capability to drive digital lead generation, and we continue to build those teams within Sonova. At the same time, somewhat unplanned, the cost to generate a lead at this point of time is significantly more expensive than before COVID-19. That is because everybody's trying to push the revenue here a little bit. In that regard, that's less of an investment into the future, it's more an investment into the current run rates, which I'm sure other people have to also factor in. With that, wanna move to the cochlear implant side and share a couple of more comments here, but also a couple of facts, particularly the breakdown into system sales and upgrade sales. You heard me talk about the 5.3% two-year CAGR versus 2019. That's probably directionally with market, if I assume that we still have a couple of hospitals who are not doing elective procedures. Clearly a recovery, in minimum, a significant first step of recovery relative to the Field Corrective Action. You can see the margin here at the 13%. If you go down to the system sales, you can see that we're still lower than we were prior to COVID-19. I think you see the elective surgeries here are probably still some customers to be convinced after the Field Corrective Action, but a very strong sales contribution from the upgrade sales side. From a segment profitability, talked about the improvements. I think ASP helps at this point of time a little bit, given that we have, particularly in the U.S., a good upgrade sales position. With that, I would hand it over to Birgit, who will guide through more of the financials, and then I'll come back to talk about how we think about the outlook here. Thank you, Arnd, and good afternoon to you all. Indeed, let me take you to the financial highlights of our first half year results, and all variances are at constant exchange rates, unless I state otherwise. As Arnd already mentioned, we ended the first half with CHF 1.6 billion in sales and saw an increase of 48.5% versus prior year, of which 46.6% was organic. Our sales growth was supported by a low base in the first half 2021 due to the COVID impact. However, when we compare our growth on a two-year CAGR basis, we see a nice 8.5% annual growth rate, as Arnd already highlighted. We continue to outperform on profitability with an EBITDA of CHF 406 million for the first half year, and a margin which is up 8.9 percentage points or seven percentage points versus the same period two years ago. Our EBITDA more than doubled, up 129.3%. Besides the comparison to a lower prior year base, it is, which was affected by COVID-19, our results are driven by continuous improvements in our cost base, both in cost of goods and operating expenses, and we'll see that later. Our adjusted EPS was up 142%. Moving to the operating free cash flow of CHF 337 million. This is up 37% versus the same period last year. This reflects our continuous focus on working capital, partly offset by an increase in safety stocks to counter supply chain issues, as Arnd already mentioned, and higher tax payments. In addition, please note that last year we posted a non-recurring cash benefit due to a patent infringement settlement. Then lastly, a few words on the balance sheet. We bought back shares worth CHF 277 million by September 30. Our net debt position is at CHF 345 million, which is up since March due to the effect of our share buyback program and also dividend payments. This leads to a net leverage ratio of 0.3 times. Moving to the next slide. Here you will see our recurring graph we always show you with the EBITDA components. Here you'll notice that our first half of EBITDA growth this year consists basically of an EBITDA related to organic growth. We keep also this slide in because you can then also see going forward certain movements between organic and M&A. Then the adjustments on this page relate to, firstly, the structural optimization initiatives for which we incurred restructuring costs of CHF 7.4 million. Secondly, CHF 5 million transaction costs, which relate to the planned acquisition of Sennheiser. Then the last light blue box in this bridge relates to the lift in profitability when we convert our constant exchange comparisons to a Swiss franc base, so basically reflecting the foreign exchange translation effect. If we move to the next slide, actually, we discussed sales at length in the previous part of the presentation, so let me jump immediately to gross profit. Here, you can see that we continue to perform well in terms of profitability by advancing our structural and continuous optimization initiatives even further and driving higher sales volumes, obviously, resulting in a gross profit margin of 73.8%, which is up 4.3 percentage points. As you can see, we could clearly more than compensate our higher transportation and components costs. As you can see from the two-year CAGR column, we continue to drive operating leverage, but I will come back to this later. We do that while investing in growth, which is really the important factor here. We already discussed the EBITDA components and adjustments on the previous page, so let me move to the next P&L lines. First, our acquisition-related amortization remains in line with prior year. The net financial expenses increased from CHF 10.3 million to CHF 19.2 million. This is driven in part by increased borrowings during the pandemic. Income taxes representing a tax rate of 14.5%. This compares to a prior year tax rate of 13.5% when we compare like for like, because last year we had a non-recurring benefit included. As I already mentioned, EPS up 142%, which reflects an EPS of 4.86 CHF compared to the 1.97 in the prior year period. This reflects our strong earnings growth. Let's now move to page 23 on the operating expenses. Here, as stated earlier, I already said that we leveraged our P&L, keeping our OpEx growth nicely below our sales growth while investing in growth. As a further note, the OpEx leverage was achieved despite the significantly lower subsidies which we received related to COVID-19 in the same period last year. As you can see from this table, we are investing strongly in R&D with a two-year compound annual growth rate of +20.4%, reflecting our continued step up in new technology investments. We equally posted an increase in our amortization of development costs in our CI business. We continue to invest in customer-facing sales and marketing, while at the same time we continue to generate savings from successful structural cost optimization initiatives, which is a recurring theme here on this page. The same applies for our general and admin costs. There as well, we are able to absorb ongoing investments in a new IT platform for our retail business, and this due to structural savings in back office consolidations. We already talked about the adjustments on the previous slide, so let's move to the next page. Here you see our operating free cash flow. For the complete detailed cash flow statement, I would like to refer you to page 36 in the appendix. On this page, I will concentrate on our OFCF, which increased by CHF 91.5 million or 37.2%. Let's look at the drivers of change besides the increase in profit before taxes. Here you see that a positive CHF 7.1 million in depreciation and amortization relates to the earlier mentioned step up in amortization of capitalized development costs in our cochlear implants business. The increase in cash taxes is due to COVID-19-related tax payment prolongations last year when we only paid actually CHF 3 million. Net working capital, this was largely stable versus the end of March, but increased versus last year. Receivable collections continued to be strong while the group allowed for an increase in inventories related to component safety stock to manage the aforementioned supply chain shortages. This is mainly in the microelectronic components area. Moving to the last slide 25, here I will take you through the main balance sheet items. Here you can see that clearly our DSO continued to be strong, while our DIO reflects an increase in inventories related to component safety stock to manage the supply chain shortages that I already discussed. Capital employed slightly increased compared to the CHF 2.855 billion, which we communicated during our year-end results in March 2021. This is driven by a rise in receivables due to the sales recovery, also again the aforementioned increase in safety stock as well as a step up in bolt-on acquisitions in our audiological care business. Our ROCE improvement is driven by our strong profit growth. Net debt, the net debt position increased versus our year-end results in March 2021, and this is driven by the share buyback program announced in May of this year, the dividend payments, and also lastly, the step up in M&A. Our net debt position, however, is still lower versus the same period last year. With that, let me hand over to Arnd for our full year outlook. Thank you, Birgit. Getting to how to think about the outlook and us keeping the guidance where it is, it's a tricky year to judge the phasing between first half and second half. Sometimes when it's tricky, we give you some incremental, let's say, thinking on how we think about the effects in first half and second, and that really should be just helping you when you're trying to judge our numbers and our outlook here. I think it's fair to say that clearly the comparison base in the first half was significantly lower than in the second half. I think that's clear given the curve we had last year. That's true for both businesses. I think while we had some stronger markets above the normal two-year CAGR in the first half year, namely the U.S. was one of those, obviously a big market versus some which are on the weaker side. I think we can't predict better than that for the next half year, but I think we all ought to be also recognizing that there's still a fourth wave coming our way and some discussions are happening in the market. I would call that kind of a put position. It's about the same as the first half year to the best of our knowledge. On the France side, which we benefit from, particularly in our wholesale business, I think we've seen very strong growth in the first half year after the reimbursement changes. We would expect that gradually slows down, not completely, but gradually. On the CI side, I think you have the highest, let's say, demand for your processor at the beginning after the launch. We expect still a good upgrades business in the second half, but probably not as strong anymore as in the first half year-over-year. That's the top-line considerations here. If you look at the bottom line, I think the ones to spell out, we started our structural optimization last year. In the first quarter, we started to have significant impact in the second quarter, but then the full impact pretty much in the second half year. In that regard, second half year already had seen lots of the benefits. Therefore, the comp base is already a lot lighter on the cost structure. Then we voiced over the supply chain constraints here, particularly on the sourcing cost side, which we quote-unquote, "Only had for 2 months in the P&L." At least, in the spirit of the guidance we gave, have now factored in for the full 6 months because it's really hard to call when this is over. Some people say 12-18, some say it's soon. At least for the next 6 months we wanted to factor it in. I think I spoke briefly about the higher lead generation costs in the markets, particularly where the markets are still slow. We're trying to drive the demand. I think, you will obviously see this with others, too. I would say that's probably similar second half to first. Just wanted to note that right now we have quite some marketing expenditures which are fully baked in in the first half year, despite the good performance. It's probably worthwhile to say if you look at the two-year CAGR, the first half year is at 8.5%, the second half year is at 8.4%. In that regard, not very dissimilar. If you look at the outlook, just for completeness, as I said, guidance unchanged for the full year. You remember the midterm targets we put out in the capital markets day. If the headwinds remain in the same order of magnitude as we've seen them in the last two months of the first half year, that's baked in. We expect resilient consumer demand, not a significant change here to the positive or negative. If that happens, it would change the perspective. The acquisition of Sennheiser is not factored into the numbers. We expect the closing by the end of the fiscal year, and we'll inform you when that is close by and then talk about the financials for the go forward. Only a slight Swiss franc positive here. When we came into the year, it was significantly stronger. We give this to you just for courtesy of the modeling, but therefore even if it is only 0%-0.1% on the top line and 1%-2% on the bottom, we had significantly higher numbers at the guidance for the full year, and we want to make you aware about those. That was our report out. I would suggest we go to Q&A, and people need to register with their questions. We know the first people have already raised questions. Therefore, Sandra, if you wanna guide us through on who gets to ask first, we try to answer them all. We will now begin the question and answer session. Anyone who wishes to ask a question or make a comment may press star and one on the touchtone telephone. You will hear a tone to confirm that you have entered the queue. If you wish to remove yourself from the question queue, you may press star and two. Participants are requested to use only handsets when asking a question. Anyone with a question may press star and one at this time. The first question comes from Patrick Wu from Bank of America. Please go ahead, sir. Perfect. Thank you very much. I'll keep it to two, please. The first one, you guys have mentioned a little bit on the M&A side that there was both a little bit more interest on bolt-on, but potentially I think something larger. I'm just curious as to strategically the kind of assets you're thinking about and where you feel like you'd like to bulk up. That's the first question. The second question, you know, very strong gross margin in the first half despite some of those supply chain pressures. If we're thinking longer term, you know, if some of those pressures remain, is there an ability to push through a little bit more pricing, let's say, with the next innovation cycle, just to sort of get, let's say, some compensation for the fact that you know, you've had to absorb a fair bit of the semi side? I'm just curious, like for like, how you feel about the pricing environment. Thanks. Patrick, thanks for the questions. You're following closely what gets published because the M&A question came just out of a discussion this morning with one of the wires. Both answers clear, audiological care is a priority for us. That would be true also for quote-unquote a larger asset. If it is a larger independent somewhere in the market we find attractive, we'd be participating in the process, and then we have to look at it. I think the other one is really if it comes to technologies which are relevant in the HI environment, also in the hearing instrument environment, probably not such big capital outlay, but you don't know until you see what it is. Yeah. Don't read into the question. I was expecting something tomorrow. It was really more a question of somebody with regard to would you consider, and we said, yes, we would consider larger M&A. From a gross margin perspective, yeah, I think we need to think about how does the inflation environment change, and I would say inflation plus microelectronics. We also need to kind of find ways to translate this into some lift on the ASP side. That's not very normal in our industry, so I think we will need to see how much of that can stick. In principle, I think given the combination of inflation and microelectronics, at least to move a little bit in this direction is I think which we are well advised to do. Fabulous. Thank you for taking the questions. You're welcome. The next question comes from Maja Pataki from Kepler Cheuvreux. Please go ahead. Yes, thank you very much for taking my questions. I'll also stick to Q2 now. Great results on AB, finally. It's good to see that this comes through. Since you're expecting a bit of a softening on the processor upgrade side in revenue, can we still expect to see a double-digit EBITDA margin? Is that what you know what you kind of budget for for the full year? That would be my first question. My second question is, you talked about the higher lead generation costs and you expect this to continue in the coming months. I believe I understood it right, that you said in the slow markets, I guess, like Germany and you know general, those kind of markets. Can you maybe give us an indication how much higher are lead generation costs? Are we talking about 10%? Are we talking 5%? Just to get a bit of a feeling for that. Thank you. Thank you, Maja. Thanks for the question. On the AB side, I think the cost structure is in a place where you should expect double-digit on the EBITDA. Keep also in mind, even if the upgrades go down a little bit, our second half tends to be stronger in the AB business. Not something to worry about from an operational performance. On the higher lead generation cost, I think it's really very dependent on the geography, but there are some geographies where you're well higher than 20%, 25% than what you were used to. It's really not just in the hearing aid environment, but I think in the markets where consumer confidence is low, I think everybody is fighting for more demand, right? I would say this is something I would expect to be in those markets until we're back to normal consumer confidence levels. Okay. Thank you very much for that. The next question comes from Oliver Metzger from ODDO BHF. Please go ahead. Good afternoon. Thanks a lot for taking my questions. The first one is on the U.S. On growth in U.S. and respective market share gains. As you said, you described 12.2% CAGR. U.S. looks like a strong outperformance if I compare them to official data. However, if I look on a one-year period, your performance looks pretty similar to the underlying market. Could you comment which segment has held you back over the last 12 months, estimate some positive comments on your performance at independent, and also VA should have had a positive contribution. That would be appreciated. The second question is also on M&A in the audiological retail space. I would say that your major competitor as well as Amplifon also seem to be more aggressive on the retail side. There's also more private equity around which is acquiring some acoustic retail. Do you see any changes in the available assets or basic on the price front? Oliver, thanks for the questions. On the U.S., I think that you make a fair point. If you look at the two-year CAGR, the first year minus the COVID-19, but from a market share gain perspective was stronger for us. That was on the back of the private label contract and us coming in VA from a very low level to above 50%. We've seen all along good performance and some market share gains in the independents in the first and in the second year, and we do get that data as an industry participant. I think underperforming quote unquote from a growth perspective is the VA where we're at that level since 12 months and longer, and the VA honestly was growing pretty much not with market, right? I think we're doing fine on the independents. We're doing fine on the private label side. I think the VA is a little bit of a headwind just because of the slower recovery of the VA, but that's the way we would look at it. Clearly, the first year was stronger from a market share gain than the second, just given VA and the private label. On the M&A side and the retailers, I think it is true that, and if it's just because we're more active overall, the number of active participants has gone up. I think we still find attractive acquisitions. If not, we wouldn't have done the ones we've done in the first half year. I think if it comes to larger targets, one really needs to take a look on how attractive is the market for oneself and what is the quote unquote price premium the bidding leads to. You have recognized there was a larger asset which traded in the first half of the year at a quite high multiple. We apparently were not going to the endpoint from a pricing perspective. It is a market we're less interested in because we have a relatively low market share. I think it really becomes a question of how strategically important is which market, and that is different by player, by geography, and that's the way we think about it. We will be thoughtful on what is a strategic priority, and we will be thoughtful on what is a meaningful price, and we still return a meaningful ROIC. Overall, yes, more people are currently active. May I just ask a follow-up to my first question, please? Sure. I just did the calculation on the VA market. Your comment basically was more about this three-year period within VA. If I look at the H1 performance, your fiscal performance versus H1 the previous year in VA, it looks like that VA has grown much stronger than the remaining market. Just due to the low base in your H1 last year. I would need to go back to this, Oliver. I'm happy to do that and get back to you. My recollection is that the VA is not as well growing. I may be off here, so allow me to go back to that. Yeah. In general, I think the strong market share position in the VA, while it is great that we sustain it, is not one where we're getting a lot of year-over-year benefit out of. Yeah. Okay, great. Thank you very much. The next question comes from Hassan Al-Wakeel from Morgan Stanley. Please go ahead. Oh, good afternoon, and thank you for taking my questions. The first one is on component costs. Could you disclose what was the impact from the higher component costs on your gross margin in the first half? What impact you expect in the second half, and perhaps your assumption on when these higher costs start to normalize again? The second one is just around the Sennheiser consumer division. Could you give some qualitative commentary as to how that business performed and whether they are seeing any headwinds from the component shortages in the industry today? Thank you. Hassan Al-Wakeel, thanks for your question. On the component cost side, allow me to comment more in an EBITDA framework. I think the two months higher prices did cost us for the full six months, around 50 basis points on the EBITDA side. We're expecting 100 to 150 basis points for the second half as a headwind, which is either slowing, getting a little bit better in the Q4 or it's at the same level as we have seen in those two months where we were impacted. Quite a meaningful order of magnitude to our EBITDA performance year-over-year. With regard to when will that improve, in the best case scenario, in the Q4 at some point. If you go to the worst-case scenario, and there's lots of different opinions on semiconductor supply, and we're not as close. We're as close as we can be, but I'm sure you find people who are closer in that industry as direct participants. I think we hear things anywhere between 6-18 months. I think we wanted to factor it in properly here, which we have for the half year. I think we need to measure as we go and in the Q4 probably wrap our head around it. What does it mean for the next year? On the Sennheiser side, not significant impact with regard to availability of product. Also some increased cost, which they have on the component. They're, in some products, buying similar chips as we do. Overall, the business is going well this year. Can't disclose an exact number, but from a growth rate in line with what we had expected for the year, perhaps a little bit better. Overall happy on their performance. The component side is more of a cost matter there, which I would look at as a short to midterm problem, but not impacting their ability to sell. Great. Thank you very much. You're welcome. The next question comes from Lisa Clive from Bernstein. Please go ahead. Hi. Just a few questions about the U.S. market. You know, I assume we continue to see pretty strong growth from the Medicare Advantage coverage of hearing aids. You have a strong partnership with UnitedHealth there. Just clearly, I don't think you'll give us, you know, hard numbers, but how does the size of that contract compare with, say, your sales in the VA channel or Costco? I mean, this is another, you know, potentially significant channel in the future. Then, second question is just, because of that contract with them, how do you interact with other Medicare Advantage players? Then lastly, any comments on the potential for Medicare expansion? I know it's been in one of the bills in Washington that may actually get passed, but just how would you think about trying to address that market opportunity? Lisa, thank you for the question. With regards to our managed care position and relationship to United, it is as a revenue contribution for us, significantly smaller than VA or Costco. I can't give you more exact numbers, but it is a meaningful size opportunity in customer, and it has grown very nicely because United is very good in switching more lives under management under this type of an offering. That's what they've done in the last two years. On the other side, we are participating in some other managed care contracts, but probably under proportional to some of our competitors. I think that's an opportunity over time for us to play in. It is something we're wrapping our head around. You may remember that we moved into the UnitedHealth relationship 3 years ago, and we were quite busy with them to build that new way and new relationship. I think we're now getting to a phase in which that's well-sustained, and we're looking for upside in the managed care environment. On the Medicare Advantage or the Medicare reimbursement, not the Medicare Advantage, it is in the second bill from the current administration, now I think included, but the bill hasn't- Yeah. That's my That's my understanding. Yeah. It's in the second bill. Yeah, yeah. It's in the what I think is called, is it social infrastructure? It's the infrastructure which is not the bridges and the roads, but it's more building the care system for the country. It is included in there. I think as we all know, that bill hasn't passed yet. Comes the question if the Democrats get it through the House. If it would happen, it would be a net positive. We would expect it to start to be relevant to our industry in 2024, most likely. The current writing of the bill is very comparable to what we're used to in other markets. It would cover the severe to profound who are under Medicare with a reimbursement for hearing aids. It would be non-competitive tendering, so it would be multiple players can participate, and the consumer can pay up but get the base fee for the hearing aids. Very much like most of the European countries, which is a positive for us. I think we need to see if this overall bill would pass, and then obviously they will be busy for two years putting this all into place. 2024 would be an incremental reimbursement benefit in the United States for severe to profound. Great, thanks. Actually, just one quick follow-up. You mentioned the structure would be similar to what you see in some other countries. In France and Germany, especially given the inflationary environment, can you just remind us the amounts that they cover? Do those automatically increase each year? I'm just trying to think through the, you know, the inflation implications. I go off memory, but I don't think they have an inflation component. I think these are fixed fees, but they do get revisited after a period of time. That's more in the, I would say 4-5-year environment. I think France is currently on the first year. In the second year, there's price changes already defined and factored in, because the introduction started for the class 1, which is the low-end and the higher end, and is stepping down for the first two years or so. I think France is clear but not improving, slightly degrading. I think Germany will come up for the next round of discussions, but that happens more on an every 5 years basis or so. I go off memory. Okay, thanks. Very helpful. The next question comes from Christoph Gretler from Credit Suisse. Please go ahead. Thank you, Sandra. Good afternoon, Arnd and Birgit. I have two questions. You know, the first also on the CI business. Could you actually, you know, talk about, you know, to what extent, you know, kind of these margin increases, gross margin driven, you know, just to get a better understanding what, you know, is still the upside opportunity there? That would be kind of the first part of the, you know, first question. The second is on that, you know, business, you know, could you elaborate on your level of provisioning given this recent, you know, press article? In particular, I noticed that, you know, in this press article it was mentioned that, you know, in Hanover, kind of the reimplantation rate would be somewhere like 30%, which no doubt must be kind of, you know, materially higher than you likely had assumed, you know, when setting up the provision. The second question relates to the balance sheet, you know, but, you know, maybe, you know, take it one by one. Hi, Chris. Thank you for taking it one by one. On the CI improvement business, I would say broader base, but a significant part comes out of the cost of goods sold in the combination of getting better in the cost per unit, but also with regard to the warranty provisions we need and we have for the ongoing business, improved quality of the products. I think there is an OpEx component because we also went through some structural improvements in the AB business. I think the third one is a good ASP development with innovation we introduce. I can't give you an exact number, but the largest of the three is the gross margin side as an improvement. On the provisioning side, first, I think one should not read too much with all respect into the claims of one institution on their failure rates. We do look at the total population worldwide, and we do this on a monthly basis. We have to from a regulatory perspective, and so certain people who get quoted may be also amongst that peer group at a high end. The number is increasing as you would expect, but is in a place where when we look at the development, we're feeling we're well provisioned with all of our product liability provisions on the CI side. Therefore, we have made no change with the closing of the books yet the first half year. We obviously look at it on a monthly basis, but ultimately think about the right positions on provisioning when we come to reporting moments. We obviously will stay close to it, but right now we feel that on product liability for CI, we're properly reserved. Now your balance sheet question. Yes. The balance sheet question is, I mean, I noticed that, you know, you still kind of now have this, you know, kind of cash, you know, of CHF 1.5 billion, you know, on hand, you know, which sounds pretty a lot, you know. On the other hand, you know, kind of if I look at the buyback, you know, the CHF 277 million that Birgit mentioned is way less than half of the up to CHF 700 million, you know, you were trying to buy back this year. Now, maybe could you kind of comment on, you know, what you think, you know, kind of, you know, would be the best strategy kind of, you know, to get to a more efficient balance sheet here? My first answer would be, keep in mind the CHF 700 million we announced with our AGM. That was in the announcements we do and things like that, or soon before the AGM, I think in the respective board meetings. Directionally, we're on the pathway, plus minus a little, to the CHF 700 million for the year. You need to keep in mind we started this six weeks into the fiscal year. That is a building block. Keep in mind, we're accelerating our M&A. We're open for other things, wanna keep some flexibility there. We also will, quote-unquote, "have to consume the acquisition of Sennheiser." If you put all of this together, it's probably a good step down for a year. We also don't wanna overdo it, particularly on the buyback side, because I don't think that's a good way of doing things. I think we will need to announce when we come to the March-April timeframe and then get back to the market. I think the best assumption right now is that we're going to look at how much we have as a debt ratio here, and then we'll take a decision on what's the right level of a buyback next year, if that's the right thing after deducting M&A and dividend. Yeah. Okay. I appreciate your comment. See you tomorrow. See you then, Chris. Thanks. See you. Thank you. As a reminder, if you wish to register for a question, please press star and one. We have a follow-up question from Maja Pataki from Kepler. Please go ahead. Yeah. Thank you very much for taking my follow-up question. I would like to start with your comments, Arnd, around consumer sentiment being subdued. I guess this is in your bigger markets, but are you referring to consumer sentiment being subdued due to government communication on the pandemic or infection rates picking up, boosters coming? Or are you talking about, you know, consumer sentiment also being a bit down due to inflation? Just to understand that. The second question would be around wage inflation. Is that something that you're seeing in some of your markets? Yeah. That's it. Thank you, Maja. When we comment or when I comment on consumer sentiment, it's pretty much with regard to how COVID-19 plays out in a specific market. What we see is when we compare the markets, it's interesting, it's less driven by infection rates, which the scientist in me would assume. You can have a country with a high infection rate, and we still see in our industry, but also in others, a lot of positive consumer confidence on going to shops. It's more tied to what is the general mood in the economy with regard to lockdown scenarios and the voiceover of the government. It may not be a surprise that Germany is one of the ones who, at least until recently, had very low infection rates. I remember less than 10 in the spring, and we still had low traffic in the industry, and I'm not just talking us, but Germany is one of the countries where we get monthly data, right? While on the other hand, you were in other markets where infection rates were significantly higher, like the U.S., and we're seeing good two-year growth rates well above the norm in the United States despite high infection rates. We at least believe it is mainly the mood of the society based on communication, lockdown scenarios and, however positive or negative, the messaging is in the marketplace. It's not the inflation side. I think, fortunately, we are in a world in which the vast majority of people who decide that they want to get a hearing aid when they are over that hump, they tend to be willing to spend the money. Keep in mind that the elder population is probably least impacted also from economical downsides because pensions are pretty fixed. Even in the U.S. where people depend on their 401(k), I think the stock market has done really well. We don't see the inflation as being a driver for less interest to engage with a hearing aid. I think we need to convince people to come to the hearing aid when they have a hearing loss. I think on a wage perspective, I think we read the publications and then make our mind up. I think in coming into the next year, yes, we will adjust a little bit more to the higher side than we have normally done. This is not a huge impact on the P&L. We have ways to mitigate this through structural cost improvements and continuous improvements. I would think that the next year we'll see probably 0.5%-2% more, but not in the range that we're concerned about it relative to our ability to manage our cost side. Great. Thank you very much for that. You're welcome. The next question comes from Veronika Dubajova from Goldman Sachs. Please go ahead. Hi, guys. Thank you. Good afternoon, and thanks for squeezing me in. I just wanna follow up, Arnd Kaldowski, on your kind of the M&A commentary that you made earlier in the press. Just curious about your desire to look at assets outside of the traditional hearing aid market, both in terms of maybe some synergies to Sennheiser, or also, you know, more broadly kind of thinking outside of the box. Just curious if that's changed at all and if that is maybe some of the M&A that you are referring to as you're spending time on. My second question, apologies if this has been asked. I got disconnected through part of the Q&A, but the Medicare expansion, I think looking at the House bill, the most recent version talks about a competitive acquisition program should indeed Medicare begin to cover hearing aids more broadly. I'd love to get your thoughts on what you think that might look like and what that might mean for ASPs in the U.S. market long term. Thank you. Thank you for the questions. I'm noting them down. On the M&A side, I think we wouldn't go overly broad at this point of time. I think there are significant opportunities in our field around hearing that I wouldn't easily go away from things which are related to hearing and the consumer journey over their life cycle. I think that's one statement. The second one with regard to Sennheiser, I think there may be attractive assets around, but I think we're for the time being first needing to catch the ball and then make sure we develop the business well. We have a temptation to first kind of get what we wanted to get out of it being good operators before we go on a journey of doing more in that space. I can never exclude anything if some magical great opportunity arises, but I think you should expect us first to get our speech and on hearables out, use the Sennheiser brand and that channel to market and make sure this is a well-run sustainable business before you think about adding anything to the portfolio there. On the House bill, you call that competitive acquisition. All I am understanding and thinking at this point of time is that this is going to be very similar to what we used at other places. At least that's the way we interpret the current wording, that there is a certain element you get paid for from the reimbursement side for hearing aids. Most likely, I don't think they're that far in the detail that may require you to have a basic product which has full functionality at that price. That would be more kind of a German model, and then you can buy up. I think there will be still lots of discussions until anything is fully into law. I think first it has to pass the budgeting process here, but then secondarily, I am sure we will have lots of opportunity to give input and others will give the input. I wouldn't even say this is definitively how it comes out at the end. I think the incoming from all we can tell is more of a German-like model where then multiple vendors will have a chance to have a basic product and can upsell from there. Okay. Because I guess, let me rephrase the question. I guess, what would be your thoughts on the upside from the expansion if we were to end up with this co-pay model, which by the way, I don't think is in the most recent version of the bill, but I know it's been discussed, versus a pure play competitive acquisition. You know, when you bid and tender for the hearing aids for the Medicare population, because I guess, you know, and there's potentially some things in between, but I'm just kinda curious your thoughts under scenario one, what would this mean for you if it is a German model? Whereas if we do get a competitive acquisition model, what do you think that would mean? I guess just, you know, a thought on what you think the ASPs in the moderate to severe category look like today. I think in the first model, you're going to see an increase of demand, but pretty normal ASPs at the end as we're used to them. Perhaps some of your additional demand comes more on the basic level, but I wouldn't see a significant price pressure on the existing business we have in that category because these people even buy them without a reimbursement contribution. You could argue perhaps it goes up a little bit because they get the reimbursement and then they still have money left in their pocket. If you go to the other model, I think you're describing something which is more like of the British model with the NHS, where you get a competitive bidding, most likely at a low set of features, perhaps as we have in NHS on older product technology, and then that segment will have a low price. But most people in that extreme case don't go for it, at least the ones who can afford better, because ultimately they see the difference in the technology. But it would be two very different outcomes on how the market evolves. The one is a bifurcation, but again, at least if you look at the NHS environment where you have such a competitive bidding at a certain price level, at the end, most people who can afford it go for the higher end. Okay. That's helpful. Your thoughts on the sort of potential penetration increase opportunity here? 'Cause my sense is adoption in the moderate to severe category is already fairly high, but I'd love to get your data on that. I think you have some potential there. It's not going to be that you're going to double your hearing aid sales in the severe to profound. I think the severe to profound have a good penetration. There is a part of the population in the U.S. who can't afford these kind of prices. They probably today then go to more of a mild to moderate product and probably get this at a private label contract partner from ours, who is more focused on the mild to moderate. I think you're going to see some penetration upgrade, probably some people going to higher prices. Again, I think it's net positive, but it's not going to be in that segment, a doubling of the market in any shape or form. Okay. That's helpful. Thank you, guys. Thank you. Once again, to ask a question, please press star and one. Gentlemen, so far there are no more questions. Okay. Thanks a lot for the following and the interest. Thanks for the, quote, unquote, "colleagues on your side" who were asking questions. That makes it worthwhile on all ends here. With that, we all wish you a good rest of the Monday and a good start into the week. Ladies and gentlemen, the conference is now over. Thank you for choosing Chorus Call, and thank you for participating in the conference. You may now disconnect your lines. Goodbye.